查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
幹細胞治療的市場規模，佔有率，趨勢分析:各類型，各細胞來源，各治療用途，各地區展望，各競爭策略，至2030年的各市場區隔預測
市場調查報告書
商品編碼
1089967

幹細胞治療的市場規模，佔有率，趨勢分析:各類型，各細胞來源，各治療用途，各地區展望，各競爭策略，至2030年的各市場區隔預測

Stem Cell Therapy Market Size, Share & Trends Analysis By Type, By Cell source, By Therapeutic Application, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 271 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球幹細胞治療的市場規模，預計今後以15.8％的年複合成長率擴大，至2030年達到7億19萬美元。幹細胞研究增加，幹細胞製造的GMP檢定設施，誘導性多功能幹細胞的需求高漲等成為市場促進因素。

本報告提供全球幹細胞治療市場相關調查，市場概要，以及各類型，細胞來源，各治療用途，各地區的趨勢，及加入此市場的主要企業的簡介等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 成長要素，阻礙因素，機會，課題的分析
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • COVID-19幹細胞治療市場的影響

第5章 市場變數及預測

  • SWOT分析
  • PESTEL分析
  • 波特的五力分析
  • 熱圖分析

第6章 全球幹細胞治療市場，各類型，2019年～2030年(100萬美元)

  • 同類幹細胞治療
  • 自體幹細胞治療

第7章 全球幹細胞治療市場，各細胞來源，2019年～2030年(100萬美元)

  • 脂肪組織來源
  • 骨髓來源
  • 胎盤/臍帶來源
  • 其他

第8章 全球幹細胞治療市場，各治療用途，2019年～2030年(100萬美元)

  • 心血管疾病
  • 發炎性疾病及自體免疫疾病
  • 肌肉骨骼系統障礙
  • 神經病變
  • 其他
  • 手術
  • 創傷、損傷

第9章 全球幹細胞治療市場，各地區，2019年～2030年(100萬美元)

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第10章 企業簡介

  • AlloSource
  • Anterogen
  • BioRestorative Therapies
  • BrainStorm Cell Therapeutics
  • Cellular Biomedicine Group
  • CORESTEM
  • Holostem Terapie Avanzate Srl
  • Hope Biosciences
  • JCR Pharmaceuticals
  • Kangstem Biotech
  • MEDIPOST
  • Mesoblast
  • NuVasive
  • Orthofix
  • Personalized Stem Cells
  • PHARMICELL
  • Pluristem Therapeutics
  • Regrow Biosciences
  • RTI Surgical
  • Smith & Nephew
  • Stempeutics Research
  • Under Pipeline Athersys
  • Takeda Pharmaceutical Company
  • ViaCyte

第9章 全球幹細胞治療市場，各地區，2019年～2030年(100萬美元)

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲
簡介目錄
Product Code: BIOT2233

Global Stem Cell Therapy Market projected to be worth USD 700.19 million by 2030.

According to SPER Market Research, the Stem Cell Therapy Market estimated to reach USD 700.19 million by 2030 with a CAGR of 15.8%. The fuels for the escalation of the Stem Cell Therapy Market are; increasing stem cell research and GMP-certified facilities to manufacture stem cells, rising demand for induced pluripotent stem cells.

Impact of COVID-19 on the Stem Cell Therapy Market

COVID-19 outbreak has a positive impact on the Stem Cell Therapy Market.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030
  • Segments covered: By Type, By Cell Source, By Therapeutic Application, By Region
  • Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa
  • Companies Covered: AlloSource, Anterogen, BioRestorative Therapies, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, CORESTEM, Holostem Terapie Avanzate S.r.l, Hope Biosciences, JCR Pharmaceuticals, Kangstem Biotech, MEDIPOST, Mesoblast, NuVasive, Orthofix, Personalized Stem Cells, PHARMICELL, Pluristem Therapeutics, Regrow Biosciences, RTI Surgical, Smith & Nephew Stempeutics Research, Under Pipeline Athersys, Takeda Pharmaceutical Company, ViaCyte

Driver: funding for stem cell research

Availability of funding for stem cell research, increasing GMP-certification approvals for cell therapy production facilities, increasing clinical trials for stem cell based-therapies; are the key driver for the expansion of this market.

Restraints:

Ethical concerns related to embryonic stem cells, costly cell-based research; are the restraint to the market growth.

Opportunity:

Growing demand for cell & gene therapies, the emergence of induced pluripotent stem cells alternative to embryonic stem cells; provide huge opportunities for the players in the market.

Global Stem Cell Therapy Market, By Type:

Based on the Type, Global Stem Cell Therapy Market is segmented as; Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.

Global Stem Cell Therapy Market, By Cell Source:

Based on the Cell Source, Global Stem Cell Therapy Market is segmented as; Adipose tissue-derived MSCs (mesenchymal stem cells), Bone marrow-derived MSCs, Placental/umbilical cord-derived MSCs, and Other Cell Sources.

Global Stem Cell Therapy Market, By Therapeutic Application:

Based on the Therapeutic Application, Global Stem Cell Therapy Market is segmented as; Cardiovascular Diseases, Inflammatory & Autoimmune Diseases, Musculoskeletal Disorders, Neurological Disorders, Surgeries, Wounds & Injuries, Other Therapeutic Applications.

Global Stem Cell Therapy Market, By Region:

North America owns the biggest share of this Stem Cell Therapy Market; this is due to growing public-private partnership funding, research grants to develop safe & effective stem cell therapy products, and increasing figure of clinical trials.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Stem Cell Therapy Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Stem Cell Therapy Market, By Type, 2019-2030 (USD Million)

  • 6.1. Allogeneic Stem Cell Therapy
  • 6.2. Autologous Stem Cell Therapy

7. Global Stem Cell Therapy Market, By Cell Source, 2019-2030 (USD Million)

  • 7.1. Adipose tissue-derived MSCs (mesenchymal stem cells),
  • 7.2. Bone marrow-derived MSCs,
  • 7.3. Placental/umbilical cord-derived MSCs, and
  • 7.4. Other Cell Sources

8. Global Stem Cell Therapy Market, By Therapeutic Application, 2019-2030 (USD Million)

  • 8.1. Cardiovascular Diseases
  • 8.2. Inflammatory & Autoimmune Diseases
  • 8.3. Musculoskeletal Disorders
  • 8.4. Neurological Disorders,
  • 8.5. Other Therapeutic Applications
  • 8.6. Surgeries,
  • 8.7. Wounds & Injuries

9. Global Stem Cell Therapy Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. AlloSource
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Anterogen
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. BioRestorative Therapies
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. BrainStorm Cell Therapeutics
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Cellular Biomedicine Group
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. CORESTEM
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Holostem Terapie Avanzate S.r.l
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Hope Biosciences
    • 10.7.5. Company details
    • 10.7.6. Financial outlook
    • 10.7.7. Product summary
    • 10.7.8. Recent developments
  • 10.9. JCR Pharmaceuticals
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.10. Kangstem Biotech
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. MEDIPOST
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. Mesoblast
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. NuVasive
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Orthofix
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. Personalized Stem Cells
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. PHARMICELL
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. Pluristem Therapeutics
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. Regrow Biosciences
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. RTI Surgical
    • 10.18.5. Company details
    • 10.18.6. Financial outlook
    • 10.18.7. Product summary
    • 10.18.8. Recent developments
  • 10.20. Smith & Nephew
    • 10.20.1. Company details
    • 10.20.2. Financial outlook
    • 10.20.3. Product summary
    • 10.20.4. Recent developments
  • 10.21. Stempeutics Research
    • 10.21.1. Company details
    • 10.21.2. Financial outlook
    • 10.21.3. Product summary
    • 10.21.4. Recent developments
  • 10.22. Under Pipeline Athersys
    • 10.22.1. Company details
    • 10.22.2. Financial outlook
    • 10.22.3. Product summary
    • 10.22.4. Recent developments
  • 10.23. Takeda Pharmaceutical Company
    • 10.23.1. Company details
    • 10.23.2. Financial outlook
    • 10.23.3. Product summary
    • 10.23.4. Recent developments
  • 10.24. ViaCyte
    • 10.24.1. Company details
    • 10.24.2. Financial outlook
    • 10.24.3. Product summary
    • 10.24.4. Recent developments

9. Global Stem Cell Therapy Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. AlloSource
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Anterogen
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. BioRestorative Therapies
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. BrainStorm Cell Therapeutics
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Cellular Biomedicine Group
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. CORESTEM
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Holostem Terapie Avanzate S.r.l
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Hope Biosciences
    • 10.7.5. Company details
    • 10.7.6. Financial outlook
    • 10.7.7. Product summary
    • 10.7.8. Recent developments
  • 10.9. JCR Pharmaceuticals
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.10. Kangstem Biotech
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. MEDIPOST
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. Mesoblast
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. NuVasive
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Orthofix
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. Personalized Stem Cells
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. PHARMICELL
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. Pluristem Therapeutics
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. Regrow Biosciences
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. RTI Surgical
    • 10.18.5. Company details
    • 10.18.6. Financial outlook
    • 10.18.7. Product summary
    • 10.18.8. Recent developments
  • 10.20. Smith & Nephew
    • 10.20.1. Company details
    • 10.20.2. Financial outlook
    • 10.20.3. Product summary
    • 10.20.4. Recent developments
  • 10.21. Stempeutics Research
    • 10.21.1. Company details
    • 10.21.2. Financial outlook
    • 10.21.3. Product summary
    • 10.21.4. Recent developments
  • 10.22. Under Pipeline Athersys
    • 10.22.1. Company details
    • 10.22.2. Financial outlook
    • 10.22.3. Product summary
    • 10.22.4. Recent developments
  • 10.23. Takeda Pharmaceutical Company
    • 10.23.1. Company details
    • 10.23.2. Financial outlook
    • 10.23.3. Product summary
    • 10.23.4. Recent developments
  • 10.24. ViaCyte
    • 10.24.1. Company details
    • 10.24.2. Financial outlook
    • 10.24.3. Product summary
    • 10.24.4. Recent developments